Advertisement
COR vs MCK
Which Stock Would AI Choose? Cencora (COR) vs. McKesson (MCK) Stock Comparison
Key Takeaways
- COR and MCK are two of the "Big Three" U.S. pharmaceutical distributors, competing on similar distribution, specialty, and oncology growth strategies.
- Both stocks underperformed the broader S&P 500 for much of 2026, though each rebounded after reporting stronger-than-expected adjusted earnings.
- COR (Cencora) is expanding margins through its OneOncology acquisition and returning capital via a newly authorized share repurchase program.
- MCK (McKesson) is driving faster earnings growth through oncology, specialty distribution, and prescription technology, and has raised its full-year outlook.
- McKesson currently shows broader catalysts, including a pending Precision Medicine Group acquisition and the planned separation of its Medical-Surgical Solutions segment.
- On relative positioning, both names offer similar sector exposure, but their growth drivers and near-term risk profiles differ in meaningful ways.
Introduction
Investors screening the healthcare distribution sector frequently land on the same two heavyweights: COR, the company now known as Cencora (formerly AmerisourceBergen), and MCK, McKesson Corporation. Both operate thin-margin, high-volume pharmaceutical supply chains, yet their recent strategic moves have diverged. This stock comparison is relevant for traders evaluating relative performance within a defensive, cash-generative industry, as well as for long-term investors weighing margin expansion against revenue scale. Because the two firms compete for the same customers and face the same drug-pricing pressures, understanding their distinct growth engines is essential to assessing market positioning in the current environment.
COR Overview and Recent Performance
Cencora (COR) is one of the world's largest pharmaceutical distributors, generating more than $300 billion in annual revenue and connecting manufacturers to pharmacies, health systems, and physician practices. In recent quarters, the company has leaned into specialty and oncology services, most notably through its acquisition of OneOncology, a management services organization that supports community cancer practices.
Recent market activity has been mixed but improving. In its most recently reported quarter, Cencora posted adjusted earnings per share (EPS) growth of roughly 12% year over year, supported by strength in its U.S. Healthcare Solutions and International segments, while consolidated adjusted operating income advanced double digits. Management also raised its full-year adjusted EPS guidance and authorized an additional share repurchase program of up to $2 billion. Sentiment has been tempered, however, by revenue headwinds including lower manufacturer list prices, the prior loss of an oncology customer, and an anticipated transition of certain Walgreens volume outside its prime vendor agreement. These factors have kept revenue growth below the company's earlier expectations even as profitability expands.
MCK Overview and Recent Performance
McKesson (MCK) is the largest U.S. pharmaceutical distributor by revenue and one of the country's oldest continuously operating businesses. Its portfolio spans North American pharmaceutical distribution, a fast-growing oncology and multispecialty platform, prescription technology solutions, and medical-surgical supply.
Recent performance has been robust at the earnings level. In its latest full fiscal year, McKesson grew adjusted EPS roughly 18% and generated approximately $6.2 billion in operating cash flow, returning the majority of it to shareholders through buybacks and dividends. Its Oncology & Multispecialty segment has been a standout, with adjusted operating profit rising sharply on provider-network expansion and acquisitions. McKesson also raised its forward earnings guidance, citing broad-based momentum, and announced a pending acquisition of Precision Medicine Group to deepen its oncology and biopharma-services capabilities. Like Cencora, however, McKesson faces branded drug-price declines and is working through the planned separation of its Medical-Surgical Solutions segment, which it is positioning as a standalone entity with a minority investment from Apollo.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of the platform's top-performing AI trading bots. While Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, only those best suited to current market conditions earn a place in this featured section. The bots vary widely by trading style, strategy, timeframe, performance statistics, and the specific sets of tickers they trade, giving users the ability to match automation to their own objectives and risk tolerance. By focusing on the most relevant, actively monitored strategies, the section helps traders cut through the noise and identify the approaches currently generating attention. Explore the Trending AI Robots page to see which strategies are positioned for today's markets.
Head-to-Head Comparison
Although Cencora and McKesson operate in the same industry, their market positioning differs in several important ways. On revenue scale, McKesson is the larger business, reporting north of $400 billion in annual revenue versus Cencora's roughly $300 billion-plus. On growth quality, McKesson has shown more consistent double-digit EPS expansion, while Cencora's recent profit gains have been partly driven by acquisitions and margin mix rather than broad-based volume growth.
Their growth drivers also contrast. McKesson is heavily invested in its oncology ecosystem—spanning The US Oncology Network, Ontada analytics, and the pending Precision Medicine Group deal—while Cencora is building a parallel specialty and oncology footprint through OneOncology and its management services organizations (MSOs). Both are exposed to the same risk factors: thin distribution margins, manufacturer list-price reductions, GLP-1 revenue that carries lower margins, and shifting customer relationships. McKesson's planned separation of Medical-Surgical Solutions adds a layer of execution complexity, while Cencora's Walgreens volume transition introduces near-term revenue uncertainty. In terms of market sentiment, both stocks have trailed the broader market, but McKesson's repeated guidance increases and faster segment profit growth have generally supported a relatively firmer narrative.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely tilt in favor of MCK in the current environment. McKesson's combination of consistent double-digit adjusted EPS growth, multiple upward guidance revisions, and a broader set of catalysts—including oncology expansion and the Precision Medicine Group acquisition—suggests stronger trend consistency and relative positioning. That said, this is a probabilistic view rather than a definitive claim. COR retains attractive qualities of its own, including expanding margins and an active buyback program, and its valuation and capital-return profile could appeal under different market conditions. Traders should weigh these trade-offs against their own time horizon and risk tolerance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COR is a Hold and MCK is a Hold.
COR's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for COR turned positive on October 06, 2026. Looking at past instances where COR's MACD turned positive, the stock continued to rise in 34 of 54 cases over the following month. The odds of a continued upward trend are 63%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 06, 2026. You may want to consider a long position or call options on COR as a result. In 49 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
COR moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where COR advanced for three days, in 240 of 390 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
COR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for COR crossed bearishly below the 50-day moving average on September 24, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 4 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 31%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where COR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 41%.
The Aroon Indicator for COR entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 13 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 25 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. COR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.011) is normal, around the industry mean (2.488). P/E Ratio (22.555) is within average values for comparable stocks, (39.020). Projected Growth (PEG Ratio) (0.636) is also within normal values, averaging (2.016). Dividend Yield (0.008) settles around the average of (0.004) among similar stocks. P/S Ratio (0.187) is also within normal values, averaging (4.260).
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
MCK in upward trend: 10-day moving average moved above 50-day moving average on October 05, 2026
The 10-day moving average for MCK crossed bullishly above the 50-day moving average on October 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 01, 2026. You may want to consider a long position or call options on MCK as a result. In 54 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 57%.
The Moving Average Convergence Divergence (MACD) for MCK just turned positive on October 05, 2026. Looking at past instances where MCK's MACD turned positive, the stock continued to rise in 34 of 53 cases over the following month. The odds of a continued upward trend are 64%.
MCK moved above its 50-day moving average on October 01, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where MCK advanced for three days, in 256 of 385 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MCK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 42%.
MCK broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MCK entered a downward trend on October 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 11 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock better than average.
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: MCK's P/B Ratio (-59.961) is very low in comparison to the industry average of (2.488). P/E Ratio (22.969) is within average values for comparable stocks, (39.020). Projected Growth (PEG Ratio) (1.616) is also within normal values, averaging (2.016). Dividend Yield (0.004) settles around the average of (0.004) among similar stocks. P/S Ratio (0.265) is also within normal values, averaging (4.260).
The Tickeron Price Growth Rating for this company is 27 (best 1 - 100 worst), indicating outstanding price growth. MCK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 70 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
COR | MCK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 21 | 28 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 71 Overvalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 25 | 11 | |
SMR RATING 1..100 | 13 | 100 | |
PRICE GROWTH RATING 1..100 | 47 | 27 | |
P/E GROWTH RATING 1..100 | 76 | 70 | |
SEASONALITY SCORE 1..100 | 90 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MCK's Valuation (12) in the Medical Distributors industry is somewhat better than the same rating for COR (71) in the Real Estate Investment Trusts industry. This means that MCK’s stock grew somewhat faster than COR’s over the last 12 months.
MCK's Profit vs Risk Rating (11) in the Medical Distributors industry is in the same range as COR (25) in the Real Estate Investment Trusts industry. This means that MCK’s stock grew similarly to COR’s over the last 12 months.
COR's SMR Rating (13) in the Real Estate Investment Trusts industry is significantly better than the same rating for MCK (100) in the Medical Distributors industry. This means that COR’s stock grew significantly faster than MCK’s over the last 12 months.
MCK's Price Growth Rating (27) in the Medical Distributors industry is in the same range as COR (47) in the Real Estate Investment Trusts industry. This means that MCK’s stock grew similarly to COR’s over the last 12 months.
MCK's P/E Growth Rating (70) in the Medical Distributors industry is in the same range as COR (76) in the Real Estate Investment Trusts industry. This means that MCK’s stock grew similarly to COR’s over the last 12 months.
| COR | MCK | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 44% |
| Stochastic ODDS (%) | 2 days ago 52% | 2 days ago 40% |
| Momentum ODDS (%) | 2 days ago 59% | 2 days ago 57% |
| MACD ODDS (%) | 2 days ago 63% | 2 days ago 64% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 66% |
| TrendMonth ODDS (%) | 2 days ago 66% | 2 days ago 70% |
| Advances ODDS (%) | 2 days ago 62% | 2 days ago 66% |
| Declines ODDS (%) | 17 days ago 41% | 17 days ago 42% |
| BollingerBands ODDS (%) | 2 days ago 52% | 2 days ago 41% |
| Aroon ODDS (%) | 2 days ago 38% | 2 days ago 37% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
COR’s FA Score shows that 2 FA rating(s) are green while MCK’s FA Score has 3 green FA rating(s).
- COR’s FA Score: 2 green, 3 red.
- MCK’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
COR’s TA Score shows that 5 TA indicator(s) are bullish while MCK’s TA Score has 5 bullish TA indicator(s).
- COR’s TA Score: 5 bullish, 4 bearish.
- MCK’s TA Score: 5 bullish, 5 bearish.
Price Growth
COR (@Medical Distributors) experienced а +4.34% price change this week, while MCK (@Medical Distributors) price change was +4.36% for the same time period.
The average weekly price growth across all stocks in the @Medical Distributors industry was +1.67%. For the same industry, the average monthly price growth was +3.33%, and the average quarterly price growth was -20.54%.
Reported Earning Dates
COR is expected to report earnings on Nov 04, 2026.
MCK is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Medical Distributors (+1.67% weekly)Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
Advertisement
COR and
Correlation & Price change
A.I.dvisor indicates that over the last year, COR has been closely correlated with MCK. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if COR jumps, then MCK could also see price increases.
| Ticker / NAME | Correlation To COR | 1D Price Change % | ||
|---|---|---|---|---|
| COR | 100% | +1.55% | ||
| MCK - COR | 71% Closely correlated | +0.64% | ||
| CAH - COR | 58% Loosely correlated | +0.69% | ||
| HSIC - COR | 12% Poorly correlated | +0.95% | ||
| YI - COR | 7% Poorly correlated | -0.32% | ||
| FOCL - COR | 6% Poorly correlated | -2.33% | ||
More | ||||
MCK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MCK has been closely correlated with COR. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if MCK jumps, then COR could also see price increases.
| Ticker / NAME | Correlation To MCK | 1D Price Change % | ||
|---|---|---|---|---|
| MCK | 100% | +0.64% | ||
| COR - MCK | 71% Closely correlated | +1.55% | ||
| CAH - MCK | 66% Closely correlated | +0.69% | ||
| HSIC - MCK | 12% Poorly correlated | +0.95% | ||
| HKPD - MCK | 10% Poorly correlated | -1.59% | ||
| FOCL - MCK | 8% Poorly correlated | -2.33% | ||
More | ||||